CAREERS

MAIN / CAREERS / GenuONE Award

GenuONE Awards

We established the GenuONE Awards to honor the employees and teams who best realize The GENUONE Way, the companywide standard for our core values of Trust and Integrity.
Awardees are excellent role models for their decision-making and activities in the workplace, marketplace and society. Awards are announced every quarter to those who have demonstrated outstanding performance of their mission while achieving brilliant teamwork harmony to deliver Genuone's unique story.

Workplace
Trust Award We build trust for each other in our workplace
  • We create an environment that shows respect for each other.
  • We maintain safe workplaces.
  • We resolve any conflicts of interest properly.
  • We manage information and resources appropriately.
Marketplace
Trust Award We build trust in our marketplaces
  • We guarantee the quality of our medicines.
  • We record and report responsibly.
  • We sustain ethical relationships.
  • We are guided by Fair Trade principles.
Society
Trust Award We build trust as a corporate citizen of society
  • We abide by ethical standards.
  • We honor our code of conduct and values.

Planning

  • Quarterly award ceremonies
  • Individual or team awards
  • Plaques and prize money

The GenuONE Awards Hall of Fame

GenuONE Awards 2022 Q4

  • Development Management Team 1
    Sungwoo Jung & Hyunsik Kang
  • Quality Control 2 Team
    Minjung Kang
  • Formulation Research Team 2
    Inpil Jung & Boyun Chang

  • Genupharma Process Team 1
    Hyunwoo Kim
  • Genupharma Process Team 1
    Jihoon Jang
  • Genupharma Process Team 1
    Sanghyeon Sim
  • Genupharma Process Team 1
    Jongbin Kim
  • Quality Control Team 1
    Chohee Kim
  • Formulation Technology Team 2
    Jusang Yoo
  • Facility Management Team 2
    Byeongseon Kim
  • CM2 Team Jonghyun Lim
  • Process Team 2
    Jinhyun An
  • Process Team 1
    Jinwon Kim
  • Analysis Research Team 2
    Seongchul Park
GenuONE Awards 2022 Q3

  • Yuna Choi, Process Team 4(Group1)
  • Changwoo Byun, CMO Group
  • Boram Choi, PV Team
  • Kijun Shin &
    Joowon Kim, HR
    Jaedong Jang, IT Team
GenuONE Awards 2022 Q1/Q2

  • Seongki Lee General Ops. Team
  • Kyo-Oh Lim Accounting Team
  • Jiyoon Kang Development Management Team 1
    Ae-Seon Kim Formulation Research 3 Team
    Saerom Kim Analysis Research 2 Team
  • Sungmoo Ha Jinrak Son Beomsoo Kim
    Process Team 1(Group1)
  • Quality Control Team
    Genupharma
GenuONE Awards 2021 Q4

  • R&D Center Idea Award
  • Gihak Lee Employee recognition
    20 Years of Employment
  • System Implement & ESG TFT
GenuONE Awards 2021 Q3

GenuONE Awards 2021 Q2

GenuONE Awards 2021 Q1

Project for the manufacture authorization of Eisai Korea’s original Pariet 10/20mg tablets

Close

Changwoo Byun, Business Division 1

Q How did you help secure MFDS authorization?
In close collaboration with every related team, I kept checking and rechecking process costs, from preparation to packaging, to negotiating supplier prices. I also organized and coordinated all the project elements we needed to achieve MFDS authorization for the manufacture of Eisai Korea’s original Pariet 10mg/20mg tablets.
Q What made the difference in getting your result?
I immediately recognized how important this project was. That led me to take on the role of a catalyst as we moved forward. I made it a point to honestly share information and ongoing developments with everyone involved and to collaborate with other teams. I completed the project with a successful agreement with the client company by keeping Genuone’s Trust and Integrity code front of mind.
Q What does winning the award mean to you?
Success in the Pariet Tablet project would have been impossible without the support and help of all sales team leaders, executives and the members of every related team. I may have been named in the award but it’s because of the hard work of many people and I absolutely won’t forget that. The award also motivates me to keep striving to become an indispensable talent for Genuone Sciences.
Close

In-young Jung, R&D Center

Q How did you help secure MFDS authorization?
We had to ensure the pharmacological equivalence for our products or we would not be able to produce Eisai Korea’s Pariet tablets. To support that process, I provided a range of data and technologies for the bioequivalence testing that was critical to moving forward.
Q What made the difference in getting your result?
Once we finally had approval for manufacturing 10mg and 20mg of Pariet tablets, we had to develop appropriate and efficient transfer product manufacturing technology. I worked with several teams to evaluate the suitability of different formulations and then to select the formulation facility that would be best for our production. I also accumulated more data that increased confidence in how our production technology could diminish technical differences that might arise in the process.
Q What does winning the award mean to you?
Being a significant contributor to the Pariet Tablet technology transfer project was particularly rewarding. I felt it seriously helped me grow as a researcher. It’s an honor just to receive this award. I want to thank everyone who participated in the project. It’s made me really happy to receive this award alongside my colleagues. We all worked hard together.
Close

Ji-yoon Kang, Development Division

Q How did you help secure MFDS authorization?
During the process of technology transfer for the Pariet 10mg/20mg tablets, I was in charge of gathering advice and opinions from each team and then communicating with everyone so each team was always up-to-speed. By leading and smoothing communications, I stayed on top of the overall product development schedule.
Q What made the difference in getting your result?
Keeping in mind that the foundation of our business is trust with our customers, I worked at maintaining close collaborations among companies and teams involved in the technology transfer. I also contributed to completing the project successfully by taking on any task I could, from getting external expert consultations to collecting all necessary data. I stayed flexible. Those steps helped the technology transfer to be carried out quickly and efficiently.
Q What does winning the award mean to you?
I really appreciate receiving one of the very first GenuONE Awards. I believe this seemingly impossible project only became possible because several teams readily collaborated to reach the same goal. Thanks again to the people in charge of the relevant teams who helped me in so many ways.
Close

Beom-sik Jo, Quality Division

Q How did you help secure MFDS authorization?
Our goal was an efficient technology transfer of Pariet 10mg/20mg tablets and I was in charge of overall quality management to achieve that as seamlessly as possible. I set up relevant and regular meetings while keeping everyone aware of managing the timeline as well as how we respond to GMP guidelines and regulations. I also systemized the technology transfer process that helped to successfully complete the transfer.
Q What made the difference in getting your result?
The technology transfer process gave me the chance to enhance our excellent pharmaceutical manufacturing technology capabilities as well as our GMP management level and, of course, our corporate image. In addition, I established ethical relationships with our customers to ensure fair trade and that will maintain good will.
Q What does winning the award mean to you?
I faced many difficulties during the technology transfer. But I was able to successfully solve them because of the help of many people. It was a challenging but good experience for me. I hope to keep learning from this experience so we can produce better products.
Close

Oral Solids Packaging Team, Production Division
(Representative: Seungsup Yoon)

Q How did you help secure MFDS authorization?
We worked to improve the packaging process during the production of Pariet 10mg/20mg tablets to ensure flawless operations.
Q What made the difference in getting your result?
Our improved process helped increase productivity by speeding up packaging, performance and efficiency. We also revamped key equipment parts of the production facility and that, plus the increased productivity, allowed us to meet the product release timeline.
Q What does winning the award mean to you?
First of all, it is an honor for the entire team. We’re all grateful to receive the GenuONE Award. There were so many obstacles in improving the packaging process of Pariet 10mg/20mg tablets, but we were able to overcome them because of teamwork and by working with trust and integrity. We want to thank the relevant teams for their help because we couldn’t have achieved it without them. Looking ahead, we will continue to work hard to be a GenuONE BEST TEAM committed to sincerity and integrity toward customers.
닫기

Jaehee Im, Quality Division

Q What were you awarded for?
I handled the due diligence for the GMP factory registration for the Crystal Genomics’ Acelex Capsule export. I managed the online inspection, resource preparation, correspondence, and follow-up. I successfully registered Kolmar Pharma’s factory at Russia’s Ministry of Food and Drug Safety (MFDS).
Q What did you accomplish?
As it was our first approval in Russia, I tried to provide as much requested information as possible and worked in close cooperation with related divisions.
Q What does winning the award mean to you?
The due diligence was not conducted in person because of COVID-19. For this reason, I had to repeatedly hold meetings with and send material to Russia every day for nearly a month. It would have been impossible without help and attention from many colleagues. With this fulfilling experience as foundation, I hope to bring about more positive results from overseas due diligence in the future.
닫기

Jihyun Jeong, Development Division

Q What were you awarded for?
The Zero X Capsule was originally planned for consignment manufacturing due to the Kolmar Pharma disposal. However, the consignment manufacturer ultimately declined production, causing the medication to be out of stock for six months. I was given the award for surveying the MFDS and managing the overall market release, which in turn helped overseas export.
Q What did you accomplish?
The medication is seasonal; it is meant for the summer (effects: weight management and loss). In order to produce the medication before the summer season arrived, I tried to help the MFDS see the situation from a different perspective by providing professional arguments from the Pharmaceutical Law and related regulations. Consequently, they were persuaded, and we were able to switch back to self-production by our company. I contributed to this year’s sales by accelerating the authorization transition and comprehensively managing the market release schedule.
Q What does winning the award mean to you?
The Zero X Capsule largely contributes to Kolmar Pharma’s sales. The speedy market release was possible because as soon as the MFDS was persuaded, necessary tasks such as preparing the raw and subsidiary materials were prioritized by related divisions with the enthusiastic cooperation of their representatives. Everyone in sales and production had a tough time with the Kolmar Pharma disposal last year so it was especially fulfilling to successfully complete this task. I want to thank the people in charge in the related divisions for that.
닫기

Relocation TFT, R&D Center

Q What were you awarded for?
The TFT was created for the R&D Center’s relocation to Dongtan. From searching for potential relocation spots to the stabilization of the center, the TFT was awarded for successfully finalizing the relocation of the R&D Center.
Q What did you accomplish?
After the relocation of the center was confirmed in 2021, there was much to do, such as screening potential relocation spots, selecting the contractor, and the conceptual design. Since this was too big a job for a small number of employees, a TFT was formed to help the entire body of researchers cooperate. Opinions from each researcher and research team were embraced as much as possible in the conceptual design stage, then the TFT members took point on the center design, construction, move, and stabilization. As a result, researchers are now able to focus on research in a comfortable environment.
Q What does winning the award mean to you?
First of all, everyone in the R&D Center TFT was pleasantly surprised by the unexpected Genuone Award. Besides the TFT members, plenty of help was given by the researchers of the R&D Center and related divisions within the company. The TFT simply thinks of winning the award as accepting it on behalf of everyone. We will think of it as an opportunity to begin again in a novel environment with pride.
닫기

SCM Team, Finance Division

Q What were you awarded for?
When it comes to the SCM Team, because of the nature of our work, the level of success is measured according to goals of cost reduction and whether those goals are achieved. 2021 was not an exception. Everyone in the team put in extra effort since it was the first cost reduction since the M&A.
We believe the award was given to us because we dutifully worked towards and achieved our cost reduction goals at the Seoul HQ and the Sejong and Jecheon Sites.
With only two months left in 2021, it is time for our team to set cost reduction goals for 2022. We will plan and strategize meticulously for next year to achieve great results again.
Q What did you accomplish?
Based on specific goals, we completely reassessed and recategorized SCM.
We analyzed and categorized each site's gaps and properties. Starting with parts which had the highest possibilities for reduction, we knocked on doors incessantly.
At the same time, we faced each stage of a problem head on and tried to secure market competitiveness.
Q What does winning the award mean to you?
The nature of SCM implicates many different divisions, so we would like to receive this award not for solely the SCM Team's achievements, but on behalf of everyone who contributed.
On that note, we would like to thank the members of relative divisions that provided much assistance.
We will continue our seamless communication between divisions as well as between division and cooperative firms so that Genuone can advance without a hitch.
The SCM Team is stationed at three different offices, Seoul, Sejong, and Jecheon, but communicates and harmonizes better than any other team. We will continue to be members of Genuone that try their best at all times. Thank you.
닫기

Young-hoon Cho & Yeonji Lee, Development Division

Q What were you awarded for?
Our company's Famotidine and Choline Alfoscerate medications' sales had increased greatly from last year, and the issue of lowering the medications' prices up to 10% through the Usage-Price Interconnected Negotiation was brought up.
Pursuing the goal of minimizing the medication price reduction rate, we formed relationships with the National Health Insurance (hereinafter "NHIS") and made various logic-based arguments. As a result, the NHIS met us in the middle and we could minimize the damage caused by the price reduction. It was a successful negotiation, and we were given this award for it.
Q What did you accomplish?
We lowered the NHIS's proposed medication price reduction rate by 1% and 2% for Famotidine and Choline Alfoscerate medications respectively. Consequently, we defended 142 million won in annual market sales.
Q What does winning the award mean to you?
Regarding Usage-Price Interconnected Negotiations, there usually aren't many valid arguments behind asking for a change in price reduction rate for generic medications like the ones we were tasked with. We faced difficulties because of this in our negotiation as well. However, with the help of the head of the Development Division, the Team Manager, and the Part manager, we were able to learn about other companies' movements and run simulations with various arguments. We obtained great results because of their help, and we thank them for helping us amid their busy schedules.
닫기

Manufacturing & Plant Planning Teams, Jecheon Site

Q What were you awarded for?
COVID-19 led to an increase in national demand for antipyretic analgesics. Due to such a situation, we received orders from consignment companies for Acetaminophen bilayer tablets adding up to about 150 batches. So many orders were received at once and we were unable to match the deadlines that the consignment companies wished to set. To resolve the issue, our Manufacturing Teams 1 and 2 worked night and day to maximize the production utilization rate of Acetaminophen bilayer tablets. As a result, we increased production and were given this award.
Q What did you accomplish?
We increased the production output of Acetaminophen tablets by operating at full capacity each equipment needed for the tablet's production. Consequently, production of the bilayer tablets increased and we were able to meet the deadlines.
Q What does winning the award mean to you?
We believe we receive this award on behalf of Manufacturing Teams 1 and 2, the Plant Planning Team, and because of what we all achieved together. Also, if it weren't for the Manufacturing teams' amazing efforts, it would have been impossible to win this award. Therefore, we would like to dedicate this award to the Manufacturing.
Team members that are working hard night and day, even now. We will continue to try our best to achieve great results from where we stand. Thank you.
top
0%/progress>